Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Longeveron (LGVN – Research Report). The associated price target remains the same with $6.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Michael Okunewitch has given his Buy rating due to a combination of factors surrounding Longeveron’s progress in Alzheimer’s disease treatment. The company recently received positive feedback from the FDA, aligning on a single pivotal Phase 2/3 adaptive study for their Alzheimer’s program. This agreement includes the potential for a Biologics License Application (BLA) based on interim data, which could significantly streamline and accelerate the path to registration.
Such advancements make Longeveron’s program more appealing in the competitive Alzheimer’s field, especially as mesenchymal stem cell therapies gain traction. The company’s strategy to initiate this pivotal study by the second half of 2026, contingent on securing a partner or non-dilutive funding, further supports the Buy rating. These developments suggest a promising outlook for Longeveron’s laromestrocel, enhancing its attractiveness for potential partnerships and investment.
According to TipRanks, Okunewitch is an analyst with an average return of -21.3% and a 27.17% success rate. Okunewitch covers the Healthcare sector, focusing on stocks such as Ocugen, Mediwound, and Lineage Therap.
In another report released yesterday, Roth MKM also reiterated a Buy rating on the stock with a $10.00 price target.